Clinical Trials Browser

Phase 2 × OTHER × Borderline Resectable Pancreatic Adenocarcinoma × Clear all

NCT04481204 2026-04-15

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2 Active not recruiting

Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT07240766 2026-02-13

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Phase 2 Recruiting

Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma